Dismissal Of AstraZeneca Securities Action Upheld

Law360, New York (June 29, 2009, 12:00 AM EDT) -- A federal appellate court has affirmed a lower court decision dismissing a proposed class action accusing AstraZeneca PLC of misleading its investors about the safety and effectiveness of Exanta, a blood thinner that failed to win the approval of the U.S. Food and Drug Administration.

In a summary order Thursday, the U.S. Court of Appeals for the Second Circuit said Judge Thomas P. Griesa of the U.S. District Court of the Southern District of New York was right when he said in June 2008 the plaintiffs...
To view the full article, register now.